Phase I Clinical Trial — First-in-Human Dose-Escalation Study
Phase I Clinical Trial (First-in-Human / Dose-Escalation Study) · Also known as: Phase 1 trial, first-in-human study, FIH study, dose-escalation study
A Phase I clinical trial is the first stage of human testing for a new drug, biologic, or intervention. Its primary objective is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) rather than therapeutic efficacy. Small cohorts of participants — typically healthy volunteers or patients with advanced disease — receive sequentially increasing doses to identify the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) that define the boundary for subsequent trials.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
+1 more
When to use it
Use a Phase I design when a new agent or combination has demonstrated sufficient preclinical efficacy and safety to justify first human exposure, and when the core question is safety, tolerability, PK/PD, and dose selection — not efficacy. It is the mandatory first step in the clinical development pathway for any new drug before proceeding to Phase II. Do not use a Phase I design when the agent already has established human PK data at the dose of interest, when you want to assess comparative efficacy (use a randomised controlled trial), or when the primary endpoint is patient-reported outcomes rather than toxicity.
Strengths & limitations
- Provides the essential human safety and PK data required before broader exposure, protecting subsequent trial participants.
- Identifies DLTs and the MTD, giving Phase II a principled dose basis rather than an arbitrary one.
- Modern adaptive designs (CRM, mTPI-2) improve dose-finding efficiency and reduce the number of participants treated at subtherapeutic doses.
- Yields early PK/PD data that can support mechanistic understanding and biomarker development.
- Regulatory frameworks (FDA, EMA, ICH E6) are well-developed, providing clear operational guidance.
- Small sample sizes (typically 15–60 participants) provide limited power to detect rare adverse events or subgroup differences.
- The traditional 3+3 design is statistically inefficient — it does not use all accumulating data and tends to underestimate the true MTD.
- Phase I findings in healthy volunteers or end-stage patients may not generalise to the target patient population in Phase III.
- PK/PD may differ substantially across patient subgroups (renal/hepatic impairment, drug-drug interactions), requiring separate Phase I substudies.
Frequently asked
Are healthy volunteers or patients enrolled in Phase I trials?
It depends on the agent. For most drugs (e.g., antibiotics, vaccines), healthy volunteers are enrolled because the risk-benefit calculation is acceptable for a person without illness. For cytotoxic oncology agents, enrolling healthy volunteers would be ethically unacceptable — patients with advanced cancer who have exhausted standard options participate instead, accepting the risk in exchange for potential benefit and to advance knowledge.
What is the difference between DLT and MTD?
A dose-limiting toxicity (DLT) is a pre-specified adverse event of sufficient severity (e.g., Grade 3–4 by NCI CTCAE) occurring within the DLT observation window that is attributable to the study drug. The maximum tolerated dose (MTD) is the highest dose at which the observed DLT rate does not exceed the pre-specified threshold — conventionally one-third of participants. The MTD is derived from the pattern of DLTs across cohorts, not from a single event.
Why use model-based designs (CRM, mTPI) instead of 3+3?
The 3+3 design makes binary go/no-go decisions using only the most recent cohort's data, ignoring all prior information. Model-based designs continuously update a statistical model of the dose-toxicity curve using all data collected so far, providing more accurate MTD estimates with fewer patients treated at non-optimal doses. Simulation studies consistently show CRM and mTPI-2 outperform 3+3 in accuracy and efficiency.
Does a Phase I trial need a control arm?
Typically no. Phase I trials are single-arm, non-randomised studies focused on tolerability and PK. A placebo or active control is occasionally added when it is important to separate drug-related from disease-related adverse events, or in vaccine trials to blind participants, but this is the exception rather than the rule.
What happens after the Phase I trial is complete?
The RP2D and the safety, PK, and preliminary PD findings inform the design of Phase II trials, which enrol a larger patient population to evaluate preliminary efficacy signals at the recommended dose. Regulatory submissions (IND updates, clinical study reports) documenting Phase I findings are required before Phase II can begin.
Sources
- Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics, 45(3), 925–937. DOI: 10.2307/2531693 ↗
- International Council for Harmonisation (ICH). (2016). ICH E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). ICH Harmonised Guideline. link ↗
How to cite this page
ScholarGate. (2026, June 3). Phase I Clinical Trial (First-in-Human / Dose-Escalation Study). ScholarGate. https://scholargate.app/en/epidemiology/phase-i-clinical-trial
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive Randomized Clinical TrialEpidemiology↔ compare
- Diagnostic Accuracy Study DesignClinical Research↔ compare
- Dose-Response AnalysisEpidemiology↔ compare
- Phase II clinical trialEpidemiology↔ compare
- Phase III clinical trialEpidemiology↔ compare
- Randomized clinical trialEpidemiology↔ compare